1. Introduction {#sec1}
===============

Recent data have emphasized that the incidence of *C*. *difficile* is on the rise because of multiple factors (use of inappropriate antibiotics, emergence of new virulent *C. difficile* strains, increased median age of the population, and multiple comorbidities). Dialysis patients are immunocompromised and hence are vulnerable to infection and sepsis from *C*. *difficile* colitis. There have been cases with *C*. *difficile* peritonitis with negative cultures from the PD catheter. In general, a positive *C*. *difficile* toxin assay and clinical resolution of symptoms with treatment are the only clue to diagnosis. In this report, we present a case of *C. difficile* peritonitis with its diagnosis and management strategy.

2. Case {#sec2}
=======

An 85-year-old black woman was admitted to the hospital with complaints of crampy abdominal pain, vomiting, and several episodes of watery diarrhea for two days. Her past medical history included end-stage renal disease (on continuous cycling peritoneal dialysis), congestive heart failure, atrial fibrillation, chronic obstructive pulmonary disease, and cervical cancer (status after total abdominal hysterectomy). She was started on peritoneal dialysis three months ago for her end-stage renal disease during a hospital admission for congestive heart failure. She was discharged to rehab, where she stayed for a month. Her last home dialysis session was a day prior to the onset of symptoms. She denied any fever, bloody stool, outside food ingestion, any sick contact, and recent travel history. On physical examination, her vital signs revealed a pulse rate of 76 beats per minute, blood pressure of 121/70 mmHg, respiratory rate of 16 breaths per minute, and a temperature of 99°F. Abdominal examination revealed nondistended abdomen with diffuse tenderness on palpation and hyperactive bowel sounds with voluntary guarding; however, dialysis catheter was intact with no surrounding erythema or purulent discharge. Initial laboratory analysis showed WBC of 13,400/*μ*L, neutrophils of 88.5%, hemoglobin of 11 g/dl, and serum albumin of 2.9 mg/dl. Peritoneal fluid analysis revealed white blood cell count in peritoneal effluent of 8359/*μ*L, with 93% neutrophil predominance. Gram strain did not show any microorganisms. Given the overall clinical status, peritonitis was suspected, and she received empiric vancomycin and ceftazidime. However, stool *C. difficile* toxin B assay returned positive. She was concurrently started on oral metronidazole. Within 24 hours, there was improvement in the clinical symptoms, and her broad-spectrum antibiotics were discontinued after a couple of days. The patient was diagnosed with PD-related peritonitis accompanying *C. difficile*-associated diarrhea, with continuation of oral metronidazole. Repeated effluent white blood cell count the day after starting metronidazole decreased to 133/*μ*L, with complete resolution of peripheral leukocytosis. Surgical consultation done on admission concluded that the peritoneal catheter was not the source of infection and, therefore, the catheter was not removed. The patient\'s symptoms resolved, and she was then discharged on a total of three weeks of metronidazole with continuation of peritoneal dialysis.

3. Discussion {#sec3}
=============

Peritonitis is a major complication of PD and is the one that may dissuade end-stage renal disease patients from choosing this form of renal replacement therapy \[[@B1]\]. The incidence of *C*. *difficile* infection has increased significantly for the last few years in the United States \[[@B2]\]. *C*. *difficile* infection has a major economic impact on costs of medical care related to hospital stay and mortality \[[@B3], [@B4]\]. Because of their immunocompromised state, PD patients are vulnerable to develop this infection. Such infections produce peritonitis by transmural translocation of the bacteria into the peritoneal cavity \[[@B5]\]. The diagnosis for it may only depend on a positive *C*. *difficile* stool toxin assay (PCR), as well as clinical resolution of the peritoneal infection with the start of treatment. In our case, the patient\'s effluent culture was negative for organisms, but positive stool PCR and clinical resolution with the appropriate treatment for *C. difficile* confirmed the diagnosis.

The disruption of the gastrointestinal barrier allows enteric bacteria to translocate into the peritoneal cavity, which is a major mechanism of peritonitis \[[@B5], [@B6]\]. Additionally, the presence of dextrose in the PD fluid allows for relatively easy seeding of the peritoneal cavity \[[@B5], [@B6]\]. Interestingly, culture-negative peritonitis is associated with lower risk of recurrent peritonitis \[[@B7]\]. Clinical presentation of *C. difficile* infection varies. It can range from mild to severe disease and can start as diarrhea/abdominal pain, low to high-grade fever, and leukocytosis. In severe cases, it may progress to hypovolemic shock. It is worth mentioning that acute diarrhea and hypoalbuminemia, which is known to result from the oozing of serum albumin from plasma into the ulcerated colonic mucosa, are good indicators of *C. difficile* intestinal disease \[[@B8]\]. While our patient\'s albumin was 2.9 mg/dl, low albumin can be seen in PD patients without *C*. *difficile* peritonitis and is not specific for *C. difficile* infection \[[@B9]\]. A definitive diagnosis of *C*. *difficile* colitis can be made by *C*. *difficile* toxin assay \[[@B10]\].

Of note, PD patients with positive peritoneal fluid culture for *C. difficile* have been reported in the literature \[[@B11]\]. In this patient, the *C. difficile* peritonitis was fatal \[[@B11]\]. In contrast, our case was culture-negative in peritoneal fluid, but there was positive stool *C. difficile* PCR, and clinical resolution with metronidazole. It is worth noting that whether the diagnosis is made by a positive stool assay or positive dialysate culture, vancomycin is now proven superior to metronidazole for the initial *C. difficile* diarrhea \[[@B12]\]. Our dialysis patient responded well to metronidazole therapy, as this was the preferred treatment agent at that time. We extended the treatment to three weeks though there are no guidelines or recommendations for treatment of *C. difficile* peritonitis for PD patients in the literature, as complete eradication in a patient with multiple comorbidities was desired.

4. Conclusion {#sec4}
=============

*C. difficile* is a common infection today. Because of their immunocompromised status, dialysis patients are vulnerable to acquiring this infection. Clinical presentation, high white blood cell count in the blood and peritoneal effluent, and a positive peritoneal fluid culture or stool PCR are helpful in establishing the diagnosis. Our case was successfully treated with oral metronidazole, which was the first-line therapy at the time. Because *C. difficile* can cause death, heightened awareness, timely diagnosis, and prompt treatment are required.
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